Maddie Meyer/Getty Images News
- Moderna (NASDAQ:MRNA) announced an amendment to its agreement with the European Commission (EC) on Tuesday to convert the existing vaccine doses in its deal to the company’s Omicron-containing bivalent vaccines for supply later in 2022.
- In addition, the 27-member bloc has agreed to procure 15M doses of Omicron-containing vaccine booster candidates from the biotech.
- Per the terms, the regular vaccine doses of mRNA-1273 that Moderna (MRNA) has agreed to supply in July and August will be delayed to later this year, with the remaining doses converted to Omicron-adapted shots, subject to regulatory clearance.
- Moderna (MRNA) is advancing two Omicron-targeted bivalent COVID-19 vaccine candidates: One is based on the Omicron subvariant BA.1, and the other is based on BA.4/5 strain.
- Both vaccines contain 25 µg of the currently authorized mRNA-1273 shot and 25 µg of Omicron-specific subvariant.